Sinai Medical Center Cedars Net Worth

The estimated Net Worth of Sinai Medical Center Cedars is at least $16.9 Million dollars as of 9 May 2017. Sinai Cedars owns over 1,145,161 units of Capricor Therapeutics Inc stock worth over $16,928,829 and over the last 10 years Sinai sold CAPR stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Sinai Cedars CAPR stock SEC Form 4 insiders trading

Sinai has made over 5 trades of the Capricor Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Sinai bought 1,145,161 units of CAPR stock worth $3,549,999 on 9 May 2017.

The largest trade Sinai's ever made was buying 1,145,161 units of Capricor Therapeutics Inc stock on 9 May 2017 worth over $3,549,999. On average, Sinai trades about 628,508 units every 168 days since 2015. As of 9 May 2017 Sinai still owns at least 4,049,959 units of Capricor Therapeutics Inc stock.

You can see the complete history of Sinai Cedars stock trades at the bottom of the page.

What's Sinai Cedars's mailing address?

Sinai's mailing address filed with the SEC is 8700 Beverly Blvd, Los Angeles, CA 90048, USA.

Insiders trading at Capricor Therapeutics Inc

Over the last 11 years, insiders at Capricor Therapeutics Inc have traded over $949,404,468 worth of Capricor Therapeutics Inc stock and bought 6,444,826 units worth $18,843,106 . The most active insiders traders include Sinai Medical Center Cedars, John Edward A.Edward St. Jo... und Gregory W Schafer. On average, Capricor Therapeutics Inc executives and independent directors trade stock every 58 days with the average trade being worth of $494,068. The most recent stock trade was executed by David B Musket on 7 August 2024, trading 34,000 units of CAPR stock currently worth $47,260.

What does Capricor Therapeutics Inc do?

capricor therapeutics, inc. (nasdaq: capr) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways. capricor’s lead candidate, cap-1002, is an “off-the-shelf” cardiac cell therapy that is currently in clinical development for the treatment of duchenne muscular dystrophy (dmd). cap-1002 consists of allogeneic cardiosphere-derived cells, or cdcs, a unique population of cells which include progenitor cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. cdcs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 140 human subjects across several clinical trials. capricor has

Complete history of Sinai Cedars stock trades at Capricor Therapeutics Inc

Capricor Therapeutics Inc executives and stock owners

Capricor Therapeutics Inc executives and other stock owners filed with the SEC include:

• Karen G. Krasney,
  Exec. VP, Gen. Counsel & Sec.
• Anthony J. Bergmann M.B.A.,
  CFO & Corp. Treasurer
• Karen Krasney,
  Executive Vice President, General Counsel
• Linda Marban,
  President, Chief Executive Officer, Director
• Dr. Linda Marbán,
  Co-Founder, Pres, CEO & Director
• Dr. Frank Isaac Litvack FACC, M.D.,
  Exec. Chairman
• Dr. Frank Isaac Litvack M.D., FACC,
  Exec. Chairman
• Joshua Kazam,
  Director
• David Musket,
  Independent Director
• Louis Manzo,
  Independent Director
• Louis Grasmick,
  Independent Director
• George Dunbar,
  Independent Director
• Earl Collier,
  Independent Director
• Deborah Ascheim,
  Chief Medical Officer
• Rachel Smith,
  Vice President - Research & Development
• Luis Rodriguez-Borlado,
  Vice President - Regenerative Therapies
• Houman Hemmati,
  Vice President - Medical & Clinical Development, New Therapies
• Thomas Copmann,
  Vice President - Regulatory Affairs and Drug Development
• Anthony Bergmann,
  Chief Financial Officer, Principal Accounting Officer
• Frank Litvack,
  Independent Executive Chairman of the Board
• Catherine Lee Kelleher,
  Consultant
• Dr. Deborah D. Ascheim,
  Consultant
• Dr. Eduardo Marbán,
  Co-Founder & Chairman of Scientific Advisory Board
• Leland Gershell,
  CHIEF FINANCIAL OFFICER
• John Edward A.Edward St. Jo...,
  
• Sinai Medical Center Cedars,
  10% owner
• Xavier Avat,
  
• Philip J Gotwals,
  
• Paul Gisbert Auwaerter,
  
• Eduardo Marban,
  10% owner
• Gregory W Schafer,
  Director
• Mike Kelliher,
  
• Karimah Es Sabar,